Panel: Biosimilar Acceptance May Be Greater Among Payers Than Previously Thought
Payers were found to be more accepting of biosimilars than expected, according to survey results presented during a panel discussion at the Academy of Managed Care Pharmacy’s 2021 Nexus meeting.
The panel discussed the current trajectory of biosimilar adoption, barriers to adoption, and how coverage of biosimilar is anticipated to evolve in the coming years.
Tasmina Hydery, PharmD, MBA, BCGP, assistant director of integrated delivery solutions at AmerisourceBergen/Xcenda, talked about the anticipation surrounding the launches of the 6 FDA-approved adalimumab biosimilars, which are scheduled to enter the US market in 2023, and the interchangeable formulation of Semglee (insulin glargine), the first biosimilar to be approved in the United States.
For the full article, visit American Journal of Managed Care.